Table 5.
Indicators of treatment failure during postoperative follow-up
| 1 month (N = 58) |
6 months (N = 59) |
12 months (N = 51) |
18 months (N = 45) |
24 months (N = 46) |
|
|---|---|---|---|---|---|
| Pain | 9 eyes (15.5%) | 6 eyes (10%) | 3 (5.9%) | 1 (2.2%) | 4 (8.7%) |
| Neovascularization of anterior segment | 10 eyes (17.2%) | 11 eyes (18.3%) | 1 (2%) | 1 (2.2%) | 3 (6.5%) |
| Further surgical intervention | 7 eyes (12.1%) | 12 eyes (20.3%) | 8 eyes (15.4%) | 5 eyes (13%) | 5 eyes (10.9%) |
| Hyphaema |
2 eyes (3.4%) |
5 eyes (8.3%) |
1 eye (2.0%) |
0 eyes | 0 eyes |
| Hypotony | 3 (5.2%) | 3 (5.1%) | 4 (7.8%) | 4 (8.9%) | 4 (8.7%) |
| Loss of light perception (cumulative) | 6 eyes | 11 eyes | 16 eyes | 16 eyes | 20 eyes |
| Additional surgery required |
3 TSCPC 2 BVT 1 BVT revision 1 TSCPC + BVT |
3 BVT 8 TSCPC 1 BVT removal |
6 TSCPC 1 TSCPC + PPV 1 Enucleation |
1 TRAB 1 Gunderson flap 1 TSCPC 1 BVT 1 BVT revision |
2 TSCPC 1 BVT removal 1 TRAB 1 Enucleation |
TSCPC trans-scleral cyclophotocoagulation, BVT Baerveldt tube, PPV pars plana vitrectomy, TRAB trabeculectomy and mitomycin C, NVI neovascularization of the iris